SCHEMBL512500

SCHEMBL512500

Cc1cc(=O)[nH]c(NC(N)=O)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.64
NPC1 O15118 2/20 0.64
POLB P06746 1/20 0.55
PKM P14618 1/20 0.55
ALOX15 P16050 1/20 0.54
KMT2A Q03164 3/20 0.50
USP2 O75604 2/20 0.50
MAPK1 P28482 2/20 0.50
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 2/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
THRB P10828 1/20 0.49
RECQL P46063 1/20 0.48
TAAR1 Q96RJ0 1/20 0.46
NCOA1 Q15788 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13738136 0.78 GAA (1.00) GAANPC1POLBPKMALOX15
SCHEMBL19820836 0.78 POLB (0.54) GAANPC1POLBPKMALOX15
SCHEMBL12462229 0.76 CYP3A4 (0.45) GAANPC1POLBALOX15KMT2A
SCHEMBL8138380 0.76 GAA (0.69) GAANPC1POLBPKMALOX15
SCHEMBL4468905 0.75 POLB (0.53) GAANPC1POLBPKMALOX15
SCHEMBL4471243 0.73 MEN1 (0.53) GAANPC1POLBPKMALOX15
SCHEMBL6128205 0.73 POLB (0.49) GAANPC1POLBPKMALOX15
SCHEMBL3216284 0.73 GAA (0.50) GAANPC1POLBPKMALOX15
SCHEMBL4468900 0.71 RECQL (0.53) GAANPC1POLBPKMALOX15
SCHEMBL5456606 0.70 NPC1 (0.64) NPC1KMT2ASMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120027698-A9 COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE COPOLYMER COMPRISING AT LEAST ONE IONIZABLE GROUP, AND COSMETIC TREATMENT PROCESS L'OREAL S.A. 2012-02-02 US claimed
US-20100278764-A1 COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE COPOLYMER COMPRISING AT LEAST ONE IONIZABLE GROUP, AND COSMETIC TREATMENT PROCESS L'OREAL S.A. 2010-11-04 US claimed
US-20070264208-A1 Cosmetic and/or pharmaceutical composition comprising at least one copolymer comprising at least one ionizable group, and cosmetic treatment process L'OREAL S.A. (FR) 2007-11-15 US claimed
EP-1797867-A1 Cosmetic or pharmaceutical composition comprising a copolymer containing at least one ionisable group, and cosmetic treatment L'Oréal (FR) 2007-06-20 EP claimed
US-12522534-B2 Self-healing optical fibers and the compositions used to create the same COVESTRO (NETHERLANDS) B.V. (NL) 2026-01-13 US disclosed
US-12491704-B2 Multi-layered optical devices COVESTRO (NETHERLANDS) B.V. (NL) 2025-12-09 US disclosed
EP-4127794-B1 SELF-HEALING OPTICAL FIBERS AND THE COMPOSITIONS USED TO CREATE THE SAME COVESTRO NETHERLANDS BV (NL) 2025-12-03 EP disclosed
US-12473395-B2 Self-healing oligomers and the use thereof COVESTRO (NETHERLANDS) B.V. (NL) 2025-11-18 US disclosed
US-20230117457-A1 METHODS OF SYNTHESIZING MULTI-HYDROGEN BONDING OLIGOMERS COVESTRO (NETHERLANDS) B.V. (NL) 2023-04-20 US disclosed
US-20230120588-A1 SELF-HEALING OLIGOMERS AND THE USE THEREOF COVESTRO (NETHERLANDS) B.V. (NL) 2023-04-20 US disclosed
US-20230116356-A1 MULTI-LAYERED OPTICAL DEVICES COVESTRO (NETHERLANDS) B.V. (NL) 2023-04-13 US disclosed
EP-4126542-A1 MULTI-LAYERED OPTICAL DEVICES Covestro (Netherlands) B.V. (NL) 2023-02-08 EP disclosed
WO-2010146147-A2 COMPOSITION FOR TREATING KERATIN FIBRES COMPRISING A BLOCK COPOLYMER, A SILOXANE RESIN AND A VOLATILE SOLVENT L'OREAL (FR) 2010-12-23 WO disclosed
US-20100278764-A1 COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE COPOLYMER COMPRISING AT LEAST ONE IONIZABLE GROUP, AND COSMETIC TREATMENT PROCESS L'OREAL S.A. 2010-11-04 US disclosed
US-20100154134-A1 COMPOSITION FOR DYEING KERATIN FIBERS, COMPRISING AT LEAST ONE POLYALKENE-BASED SUPRAMOLECULAR POLYMER, AT LEAST ONE PIGMENT AND AT LEAST ONE VOLATILE SOLVENT L'OREAL S.A. (FR) 2010-06-24 US disclosed
US-20100158832-A1 COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR POLYMER AND METHOD FOR MAKING UP THE SKIN AND/OR LIPS EMPLOYING A COMPOSITION COMPRISNG A SUPRAMOLECULAR POLYMER L'OREAL S.A. (FR) 2010-06-24 US disclosed
WO-2010057920-A2 METHOD FOR MAKING UP OR CARING FOR EYELASHES OR EYEBROWS USING A POLYALKENE-BASED SUPRAMOLECULAR POLYMER L'OREAL (FR) 2010-05-27 WO disclosed
US-20070264208-A1 Cosmetic and/or pharmaceutical composition comprising at least one copolymer comprising at least one ionizable group, and cosmetic treatment process L'OREAL S.A. (FR) 2007-11-15 US disclosed
US-20070189991-A1 Cosmetic compositon comprising a (Thio)urethane/ (thio)urea copolymer capable of forming at least 3 hydrogen bonds, and a method of cosmetic treatment L'OREAL S.A. (FR) 2007-08-16 US disclosed
EP-1797867-A1 Cosmetic or pharmaceutical composition comprising a copolymer containing at least one ionisable group, and cosmetic treatment L'Oréal (FR) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070189991-A1 Cosmetic compositon comprising a (Thio)urethane/ (thio)urea copolymer capable of forming at least 3 hydrogen bonds, and a method of cosmetic treatment KRT18, TST, CTH GAA 2708/4885NPC1 4772/4885POLB 625/4885
US-20100158832-A1 COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR POLYMER AND METHOD FOR MAKING UP THE SKIN AND/OR LIPS EMPLOYING A COMPOSITION COMPRISNG A SUPRAMOLECULAR POLYMER CUTA, PARG, DSG1 GAA 1595/4885NPC1 3433/4885POLB 230/4885
US-20070264208-A1 Cosmetic and/or pharmaceutical composition comprising at least one copolymer comprising at least one ionizable group, and cosmetic treatment process KRT18, DSG1, DSC1 GAA 1408/4885NPC1 3377/4885POLB 960/4885
US-20100154134-A1 COMPOSITION FOR DYEING KERATIN FIBERS, COMPRISING AT LEAST ONE POLYALKENE-BASED SUPRAMOLECULAR POLYMER, AT LEAST ONE PIGMENT AND AT LEAST ONE VOLATILE SOLVENT KRT18, JUP, DSG1 GAA 4294/4885NPC1 4230/4885POLB 972/4885
US-20120027698-A9 COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE COPOLYMER COMPRISING AT LEAST ONE IONIZABLE GROUP, AND COSMETIC TREATMENT PROCESS KRT18, DSG1, DSC1 GAA 1243/4885NPC1 3503/4885POLB 775/4885
US-20100278764-A1 COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE COPOLYMER COMPRISING AT LEAST ONE IONIZABLE GROUP, AND COSMETIC TREATMENT PROCESS KRT18, DSG1, DSC1 GAA 1243/4885NPC1 3503/4885POLB 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.